[CONSOLIDATION_METHOD_TITLE] [CONSOLIDATION_METHOD]
Related Companies
[]
Related Funds
[]
English
oda_MaterialEventDisclosureGeneralAbstract|
Material Event Disclosure General
oda_UpdateAnnouncementFlag|
Update Notification Flag
Hayır (No)
oda_CorrectionAnnouncementFlag|
Correction Notification Flag
Hayır (No)
oda_DateOfThePreviousNotificationAboutTheSameSubject|
Date Of The Previous Notification About The Same Subject
-
oda_DelayedAnnouncementFlag|
Postponed Notification Flag
Hayır (No)
oda_AnnouncementContentSection|
Announcement Content
oda_ExplanationSection|
Explanations
oda_ExplanationTextBlock|

According to the letter dated 07.02.2026 from the R&D Incentives Directorate General of the Ministry of Industry and Technology of the Republic of Türkiye, our subsidiary Elixir Pharmaceutical Research and Development Inc. has been granted R&D Center status as of 03.02.2026.

With this status, our subsidiary will be able to benefit from the following deductions, exemptions, supports and incentives under Law No. 5746 on the Support of Research, Development, and Design Activities:

• R&D and design deduction
• Income tax withholding incentive
• Social security premium support
• Stamp tax exemption
• Customs duty exemption
• Support for eligible programs
• VAT exemption for the purchase of new machinery and equipment.

We respectfully announce this to the public and our investors.